GO3 Launches Line of Health-Focused Products with Partner Dav...(d Findus Ltd. David Beckham is an ideal ...),Health
Navigation Links
GO3 Launches Line of Health-Focused Products with Partner David Beckham
Date:2/26/2008
d Findus Ltd. "David Beckham is an ideal partner and healthy lifestyle role model and we look forward to GO3 Omega-3 fish oil supplements making a positive impact on American consumers of all ages."
"Playing soccer since I was a young boy has taught me that good nutrition and a balanced diet is important to remaining healthy and fit," said David Beckham. "I'm teaming up with GO3 to let adults and children know there's an easy and simple way to include Omega-3 oils into their daily life."
Pricing and Availability
A 30-day supply of GO3 Omega-3 fish oil supplements, in unique adult and junior formulas, are available for $21.95. Shipping and handling plus applicable sales tax will be added based on order size and state of residence. GO3 Original Omega-3 fish oil supplements are available in packages of 60 individually-sealed capsules made from vegetarian-friendly fish gelatin. GO3 Junior Chewable Omega-3 fish oil supplements are available in packages of 60 individually-sealed capsules. Each chewable strawberry flavored capsule is enclosed in fun soccer field-illustrated blister packaging.
For easy online shopping and more information on GO3, as well as helpful information about consumer health topics and fun, family activities to promote higher physical activity levels and better food choices, visit http://www.go3.com.
About GO3
GO3 has partnered with David Beckham to promote both fitness and a
healthier lifestyle for all ages through the GO3 product line. Available
online in the U.S. market at http://www.go3.com, GO3 supplements are a
family- friendly way to get the recommended daily amount of
health-supporting Omega-3 nutrients every day. Understanding that it can be
difficult for busy families to make healthy choices part of a daily routine
each and every time, David Beckham endorses the GO3 brand as an advocate
for good overall min
'/>"/>
| SOURCE GO3 Ltd Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
(Date:11/23/2009)...lation of arsenic compounds appears to cause oxida...ity, according to a new study published online Nov...stitute . , Although biomethylation was once bel...ught to enhance its toxicity and potentially its c...c biomethylation in oxidative DNA damage in mice, ...
(Date:11/23/2009)...s saw their odds drop by 63 percent with moderate-...ov. 23 (HealthDay News) -- Moderate-to-high intens...ay help reduce stroke risk in older men but not in...d almost 3,300 men and women, average age 69, in M...uring that time, there were 238 strokes among the ...
(Date:11/23/2009)...artnershipswithMinorityBanksin Washington D.C.... S.C. IntendedtoSpurEconomicGrowthandRevitalizati...ire/--DaVita,thenation,sleadingproviderofdialysiss...heAnacostiacommunityfora$1millioninvestmentinIndus...oritycommunities. ,, DaVita,sinvestmentinWashin...
(Date:11/23/2009)...LLAS,Nov.23/PRNewswire/-- ,, WHAT: ,, The...erylCompanies, thenation,sleadinghealthcareexclus...tivelyreachconsumersineverygenerationwithapositive...erCEOofMinuteClinic,thisWebinarwillsupplementHowe,...nalPerspective,"whichdiscusseshowconsumerswillulti...
(Date:11/23/2009)...WYORK,Nov.23/PRNewswire/--Howistheeconomyaffecting...mp;SaatchiWellnessonWellness&theEconomy,theeco...ftsfromahealthylifestyleofexerciseanddiettoonethat...mate. ,, Thesurvey,smostdramaticfindingwasthech...romatraditionalfocusonhealthandwellbeingtotoday,sm...
Breaking Medicine News(10 mins):Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4Health News:Tips to Improve Healthcare Customer Service Across All Generations 2Health News:Being Well Is About Reinvention - Not Health 2Health News:Being Well Is About Reinvention - Not Health 3[0] News brief: Arsenic biomethylation required for oxidative DNA damage[1] Vigorous Exercise Cuts Stroke Risk for Men, Not Women[1] DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities[0] Tips to Improve Healthcare Customer Service Across All Generations[0] Being Well Is About Reinvention - Not Health
...vation Management Group,Inc. (IMG) announced today...low cost, full screen magnification software. Most... designed for individuals who have extreme visual,...riced within the reach of the average computer use...
...it National,Patient Advocate Foundation (NPAF), re...ted nationally in more than a decade through our,d...Foundation (PAF),continues to routinely receive in...g and chronic conditions, continue to,seek informa...
...sed wisely and in the right patients, experts say ...h Friday,s announcement of almost $5 billion to be...by the now-withdrawn painkiller Vioxx, the drug,s ...he focus back on the medications once again. , Cox...
...nome Sciences,Inc. (Nasdaq: HGSI ) announced toda...or Focus Conference will be webcast and may be acc....newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) A m... Investors interested in listening to the live web...
...Nasdaq: MASI ),the inventor of Pulse CO-Oximetry ...imetry, announced today that the Pricing Committee...stockholder rights plan. "This plan is designed t...ce to all stockholders or are otherwise,not in the...
...ng-Plough,Corporation (NYSE: SGP ) will provide a... Bertolini, executive vice president and chief fin...are Conference in Phoenix,Ariz., on Nov. 13, 2007,...-Plough corporate Web site, http://www.schering-pl...
Other Medicine News:Health News:IMG Announces an Affordable Full Screen Software Magnifier for Home and Business Users 2Health News:National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs) 2Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 2Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 3Health News:Vioxx Settlement Puts Painkillers Back in the Spotlight 4Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3IMG Announces an Affordable Full Screen Software Magnifier for Home and Business UsersNational Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)Vioxx Settlement Puts Painkillers Back in the SpotlightHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus ConferenceMasimo Corporation Adopts Stockholder Rights PlanSchering-Plough to Webcast CFO Robert J. Bertolini's Presentation at 2007 Credit Suisse Health Care Conference
(Date:11/23/2009)...wswire-FirstCall/-- CryoLife,Inc. (NYSE: CRY ),ani...tissueprocessingcompany,announcedtodaythatitissche...ualHealthCareConferenceatTheNewYorkPalaceHotelonDe...hiefexecutiveofficerofCryoLife,Inc.,willprovideaco...ntsandhostaquestionandanswersessionat4:30p.m.Easte...
(Date:11/23/2009)....23/PRNewswire-FirstCall/--WoundManagementTechnolo...oviderofspecialtymedicalproducts,announcedthatitha...ehensivemanagementbusinessupdatetoillustratethedev...alesincreased33.5%to$102,926vs.Q32008salesof$77,08...o$3,327,892vs.Q32008shareholderequityof$(321,257) ...
(Date:11/23/2009)...23/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: ...byitspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),wil...theongoingphase2btrialofRG7128,afirst-in-classnucl...ronichepatitisCvirus(HCV)infection.Thedecisionwasr...toringCommittee(DMC)ofallavailablesafetydatafromth...
Breaking Medicine Technology:CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Children Uniting Nations Russell Simmons Mos Def David Archuleta Terrence Howard Gabrielle Union Vivica Fox Elise Neal and Shawn King Visit 48163 1Children Uniting Nations Russell Simmons Mos Def David Archuleta Terrence Howard Gabrielle Union Vivica Fox Elise Neal and Shawn King Visit 48163 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 1CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 2CVS Caremark Ranks Among 50 Best Fertility and Adoption Friendly Workplaces in America 48156 3[0] CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference[0] Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update[0] Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
... an emerging,research-based pharmaceutical company...ation (FDA) has granted Orphan Drug Designation to...tment of chronic lymphocytic,leukemia (CLL). A Pha...ic,in Rochester, Minnesota where researchers are s...henon E in CLL patients., "The FDA Orphan Drug De...
...a,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced...inical trial with AZ-004 (Staccato(R) loxapine).,A...eloped for the treatment,of acute agitation in pat...za believes the novel, non-invasive nature and rap...inhaled loxapine administration via the,Staccato s...
Other Medicine Technology:Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |